ArticleCureus2025
Comparative Efficacy and Toxicity of Weekly Carboplatin Versus Cisplatin in Concurrent Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma: A Quasi-experimental Study From Bangladesh.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Cisplatin-based concurrent chemoradiotherapy (CCRT) is the standard care for locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). However, its toxicity limits use, especially in resource-limited settings. Carboplatin, with less toxicity, is a potential alternative, yet comparative South Asian evidence is scarce. This study compared the efficacy and toxicity of weekly carboplatin versus cisplatin, concurrently with radiotherapy in patients with LA-SCCHN. Methodology This quasi-experimental study was conducted at a tertiary care hospital in Bangladesh. A total of 90 patients with histologically confirmed LA-SCCHN were non-randomly allocated to receive either weekly cisplatin (40 mg/m²) or weekly carboplatin (area under the curve (AUC)-2), concurrently with external beam radiotherapy (66 Gray over 6.5 weeks). Treatment response was evaluated using Response Evaluation Criteria in Solid Tumors version 1.1, and toxicity was graded per Common Terminology Criteria for Adverse Events version 3.0. Statistical analysis was performed using SPSS version 25 (IBM Corp., Armonk, NY, USA), with a p-value <0.05 considered significant. Results Both cisplatin and carboplatin demonstrated comparable complete response rates of 17 (37.8%) versus 18 (40.0%) at six weeks, 18 (40.0%) versus 20 (44.4%) at 12 weeks, and 19 (42.2%) versus 22 (48.9%) at 24 weeks, with statistically insignificant differences. Cisplatin was associated with higher rates of mucocutaneous and gastrointestinal toxicities, while carboplatin was linked to increased hematologic toxicity, particularly thrombocytopenia (p = 0.040). Late toxicities were similar across groups. Conclusions Weekly carboplatin demonstrated comparable efficacy to weekly cisplatin, with radiotherapy for LA-SCCHN, with a distinct toxicity profile. Carboplatin may be a clinically viable alternative for patients unsuitable for cisplatin, particularly in settings with limited supportive care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.